$heff's $tation of $tocks & $olid DD

[rocketeer357]

BSTC- fully agree that this is one of the best risk/reward PDUFA plays near term. Volume lately has been minisucle, but that'll change when folks connect BSTC with AUXL.

Highlights from the BSTC 10 May CC:

-We expect to report top line data from both the Phase II human lipoma trial and Chien-804 in canine lipoma in the second half of 2013.

-Data (for frozen shoulder) showed statistically significant improvements from baseline compared to control group in forward flexion and pain and function in two of the doses. There were no drug-related serious adverse events reported and all treatment-related adverse events were consistent with XIAFLEX use in other approved and potential indications. Most importantly, the data support progression into the next stage of development which Auxilium expects to initiate in the second half of 2013.

-Plans to launch XIAFLEX in Canada in Q2 2013

-We were pleased to announce this past quarter that the Journal of Urology electronically published data from the Peyronie’s Disease Phase III IMPRESS trial. If approved, XIAFLEX is expected to be the first and only biological therapy indicated for the treatment of Peyronie’s Disease. PDUFA date September 6

-The XIAFLEX pipeline is abundant with one indication on the market, another awaiting potential US approval and several more in clinical testing.

-Q1 2013 was $4.0 million compared to $2.6 million for the same period in 2012.and net income was $1.4 million for Q1 2013 or $0.21 per basic share and $0.19 per diluted share compared to a net income of $0.7 million or $0.12 per basic and $0.11 per diluted share for the same period in 2012

-As of March 31, 2013, we had cash and cash equivalents and investments of $12.2 million compared to $8.5 million as of December 31, 2012.


Last week, AUXL reported Global XIAFLEX revenue grew to $18.9 million with our U.S. XIAFLEX revenue of $15 million increasing 26% over the second quarter of last year.

AUXL CC transcript is worth a read- they clearly have big plans for XIAFLEX as the recent deal with Sobi demonstrates.

seekingalpha.com/article/1596982-auxilium-pharmaceuticals-management-discusses-q2-2013-results-earnings-call-transcript?source=yahoo

BSTC has a share buyback program in place. 6.35 million shares outstanding with a tiny float of 4.24 million. Institutions hold almost 40%, insiders the same.

BSTC CC this Thursday 8 August at 8:30 AM to discuss 2nd quarter results.